文献速递湿疹皮炎与荨麻疹

特应性皮炎不同定义对患病率估计及关联风险因素的影响

Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors.
PubMed 文献 · Br J Dermatol · 2019-06-26

该研究系统回顾了文献中特应性皮炎(AD)的操作性定义,并在两个基于人群的出生队列(MAAS和Ashford)的5岁儿童中,评估了常用「病例」和「对照」定义对AD患病率估计及关联风险因素(包括丝聚蛋白突变)的影响。结果显示,不同病例定义下患病率在MAAS为22%~33%、Ashford为12%~22%,临床不确定区域分别为32%~44%和9%~29%;

要点

  • AD不同操作性定义导致患病率估计差异明显,MAAS为22%~33%,Ashford为12%~22%。
  • 预测模型临床不确定区域随定义变化,MAAS为32%~44%,Ashford为9%~29%。
  • 与丝聚蛋白突变的关联随病例和对照定义不同而变化,提示需统一AD定义。

核心结论

  • 使用不同的AD定义会导致患病率估计、预测模型性能及与风险因素的关联出现实质性差异。

研究设计与样本

  • 研究首先回顾文献中AD的操作性定义,然后在两个基于人群的出生队列(MAAS和Ashford)的5岁儿童中测试常用病例和对照定义的影响。

主要发现

  • 共回顾45项研究,识别出59种不同的AD定义。
  • 不同病例定义下,MAAS患病率为22%~33%,Ashford为12%~22%。
  • 临床不确定区域在MAAS为32%~44%,Ashford为9%~29%。
  • 使用相同病例定义但不同对照定义时,与丝聚蛋白突变的关联也存在差异。

关键数值与推荐

  • 从59种定义中选择了4种常用「病例」定义和2种「对照」定义进行分析。
  • 临床不确定区域定义为AD后验概率在25%至60%之间。

临床怎么用

  • 临床研究和实践中应意识到AD定义的选择会显著影响患病率估计和风险因素关联。
  • 建议在研究中明确报告所使用的AD病例和对照定义,以利于结果比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD), and no uniform clinical definition. OBJECTIVES: To investigate to what extent operational definitions of AD cause fluctuation in the prevalence estimates and the associated risk factors. METHODS: We first reviewed the operational definitions of AD used in the literature. We then tested the impact of the choice of the most common definitions of 'cases' and 'controls' on AD prevalence estimates and associated risk factors (including filaggrin mutations) among children aged 5 years in two population-based birth cohorts: the Manchester Asthma and Allergy Study (MAAS) and Asthma in Ashford. Model performance was measured by the percentage of children within an area of clinical indecision (defined as having a posterior probability of AD between 25% and 60%). RESULTS: We identified 59 different definitions of AD across 45 reviewed studies. Of those, we chose four common 'case' definitions and two definitions of 'controls'. The prevalence estimates using different case definitions ranged between 22% and 33% in MAAS, and between 12% and 22% in Ashford. The area of clinical indecision ranged from 32% to 44% in MAAS and from 9% to 29% in Ashford. Depending on the case definition used, the associations with filaggrin mutations varied, with odds ratios (95% confidence intervals) ranging from 1·8 (1·1-2·9) to 2·2 (1·3-3·7) in MAAS and 1·7 (0·8-3·7) to 2·3 (1·2-4·5) in Ashford. Associations with filaggrin mutations also differed when using the same 'case' definition but different definitions of 'controls'. CONCLUSIONS: Use of different definitions of AD results in substantial differences in prevalence estimates, the performance of prediction models and association with risk factors. What's already known about this topic? There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD) and no uniform clinical definition. This results in different definitions utilized in AD studies, raising concerns on the generalizability of the results and comparability across different studies. What does this study add? This study has shown that different definitions of 'cases' and 'controls' have major impacts upon prevalence estimates and associations with risk factors, including genetics, in two population-based birth cohorts. These findings suggest the importance of developing a consensus on AD definitions of both 'controls' and 'cases' to minimize biases in studies.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nakamura T, Haider S, Colicino S, et al. Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors. Br J Dermatol. 2019. PMID: 30822368. doi:10.1111/bjd.17853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。